Fortress Biotech, Inc. (FBIOP) EBT Margin (2015 - 2026)
Fortress Biotech (FBIOP) posted quarterly EBT Margin of 44.2% for Q4 2025, up 12715.0% year-over-year from N/an in Q4 2024, and down 188.03% quarter-over-quarter from 50.21% in Q3 2025.
Fortress Biotech, Inc. (FBIOP) EBT Margin (2015 - 2026) Analysis & Trends
Fortress Biotech's EBT Margin history runs 11 years deep, the most recent figure standing at 44.2% for Q4 2025.
- In Q4 2025, EBT Margin rose 12715.0% year-over-year to 44.2%; the TTM figure through Dec 2025 stood at 103.12% (up 10500.0% YoY), while the FY2025 annual figure was 54.76%, up 15424.0% from the prior year.
- EBT Margin for Q4 2025 stood at 44.2%, down from 50.21% in the prior quarter.
- The five-year high for EBT Margin was 99.2% in Q4 2022, with the low at 30500.0% in Q2 2023.
- The 5-year median for EBT Margin is 268.41% (2021), against an average of 4768.16%.
- The sharpest annual moves came in 2023 and 2024: EBT Margin slumped 3020425 bps in 2023, then jumped 3030414 bps in 2024.
- Fortress Biotech's EBT Margin stood at 101.53% in 2021, then jumped by 198 bps to 99.2% in 2022, then slumped by 289 bps to 187.49% in 2023, then climbed by 9 bps to 171.35% in 2024, then soared by 74 bps to 44.2% in 2025.
- Business Quant data shows FBIOP's EBT Margin at 44.2% in Q4 2025, 50.21% in Q3 2025, and 260.25% in Q2 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.93% |
| Dec 31, 2025 | -44.20% |
| Sep 30, 2025 | 50.21% |
| Jun 30, 2025 | -260.25% |
| Mar 31, 2025 | -192.39% |
| Dec 31, 2024 | -171.35% |
| Sep 30, 2024 | -182.00% |
| Jun 30, 2024 | -195.86% |
| Mar 31, 2024 | -294.21% |
| Dec 31, 2023 | -187.49% |
| Sep 30, 2023 | -5,814.84% |
| Jun 30, 2023 | -30,500.00% |
| Mar 31, 2023 | -510.70% |
| Dec 31, 2022 | 99.20% |
| Sep 30, 2022 | -14,576.92% |
| Jun 30, 2022 | -295.75% |
| Mar 31, 2022 | -8,575.04% |
| Dec 31, 2021 | -101.53% |
| Sep 30, 2021 | -276.57% |
| Jun 30, 2021 | -29,336.13% |